3,775,245 results match your criteria Cancer Therapy [Journal]


Electrochemotherapy in the Treatment of Breast Cancer Metastasis to the Skin and Subcutaneous Tissue - Multicenter Experience.

Oncol Res Treat 2018 Dec 12;42(1-2). Epub 2018 Dec 12.

Introduction: Breast cancer is responsible for more than 50% of cutaneous metastases. One of the treatment options is electrochemotherapy (ECT). It is an effective method of local tumor ablation through the application of electroporation. Read More

View Article
December 2018
1 Read

Palliative Care in Patients with Hematological Malignancies.

Authors:
Karin Oechsle

Oncol Res Treat 2018 Dec 12;42(1-2). Epub 2018 Dec 12.

Patients with hematologic malignancies (HM) nowadays rarely receive palliative or hospice care, and studies on potential effects of integrated palliative care are rare. This narrative review provides a comprehensive overview on their current end-of-life care, first data on integrated specialist palliative care (SPC) and potential barriers. Symptom burden and distress in patients with HM seem to be comparable to other cancer patients, but their performance status and specific symptoms are even worse. Read More

View Article
December 2018

Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.

Digestion 2018 Dec 7:1-7. Epub 2018 Dec 7.

Background: Nonalcoholic-fatty-liver-disease/nonalcoholic steatohepatitis (NAFLD/NASH) is expected to become the leading liver disease worldwide. Typical liver-related complications are fibrosis, cirrhosis, and the development of hepatocellular cancer (HCC) with the need for liver transplantation. Up to now there is no approved pharmacotherapy. Read More

View Article
December 2018

Efficacy and Safety of Amrubicin in Non-Small-Cell Lung Cancer Patients Beyond Third-Line Therapy.

Oncol Res Treat 2018 Dec 12;42(1-2). Epub 2018 Dec 12.

Background: There are no standard cytotoxic treatments for non-small-cell lung cancer (NSCLC) patients beyond third-line therapy. The purpose of this study was to evaluate the efficacy and safety of amrubicin in pretreated NSCLC patients.

Methods: The records of NSCLC patients who received amrubicin monotherapy as a third or later line of chemotherapy at Shizuoka General Hospital between April 2007 and March 2015 were retrospectively reviewed. Read More

View Article
December 2018

PGK1 is a Potential Survival Biomarker and Invasion Promoter by Regulating the HIF-1α-Mediated Epithelial-Mesenchymal Transition Process in Breast Cancer.

Cell Physiol Biochem 2018 11;51(5):2434-2444. Epub 2018 Dec 11.

The Clinical Medical Testing Laboratory, Northern Jiangsu People's Hospital and Clinical Medical College of Yangzhou University, Yangzhou, China.

Background/aims: Glycolysis, a multi-step enzymatic reaction, is considered to be the root of cancer development and progression. The aim of this study is to figure out which glycolysis enzyme participates in the progression of breast cancer and its possible mechanisms.

Materials: We firstly screened out PGK1 by performing an RT-PCR array of glycolysis-related genes in three paired breast cancer samples, and further investigated PGK1 using TCGA and our own database. Read More

View Article
December 2018

Circular RNA circPVT1 Promotes Proliferation and Invasion Through Sponging miR-125b and Activating E2F2 Signaling in Non-Small Cell Lung Cancer.

Cell Physiol Biochem 2018 7;51(5):2324-2340. Epub 2018 Dec 7.

Department of Prevention Medicine, School of Public Health, Mudanjiang Medical College, Mudanjiang City,

Background/aims: Circular RNAs (circRNAs) are key regulators in the development and progression of human cancers, however its role in non-small cell lung cancer (NSCLC) tumorigenesis is not well understood. The aim of this study is to identify the expression level of circPVT1 in NSCLC and further investigated its functional relevance with NSCLC progression both in vitro and in vivo.

Methods: Quantative real-time PCR was used for the measurement of circPVT1 in NSCLC specimens and cell lines. Read More

View Article
December 2018

lncRNA SNHG8 Promotes the Tumorigenesis and Metastasis by Sponging miR-149-5p and Predicts Tumor Recurrence in Hepatocellular Carcinoma.

Cell Physiol Biochem 2018 7;51(5):2262-2274. Epub 2018 Dec 7.

Background/aims: Long noncoding RNAs (lncRNAs) are aberrantly expressed in multiple malignant tumors involved in tumor growth and metastasis. Accumulating data show that small nucleolar RNA host gene (SNHG) 1/12/20 plays a key role in the progression of hepatocellular carcinoma (HCC). However, the molecular mechanisms by which SNHG8 contributes to HCC remain elusive and merit exploration. Read More

View Article
December 2018

circZMYM2 Competed Endogenously with miR-335-5p to Regulate JMJD2C in Pancreatic Cancer.

Cell Physiol Biochem 2018 7;51(5):2224-2236. Epub 2018 Dec 7.

Departments of Urology, the Third Affiliated Hospital of SooChow University, Changzhou,

Background/aims: We aimed to study the involvement of circZMYM2 (hsa_circ_0099999) in pancreatic cancer (PC) cell proliferation, apoptosis and invasion and to figured out the underlying mechanism of circZMYM2 regulating miR-335-5p and JMJD2C.

Methods: CircRNA differential expressions in twenty PC samples and paired normal tissue samples were analyzed using Arraystar Human CircRNA microarray V1. CircZMYM2 expression level was determined via qRT-PCR. Read More

View Article
December 2018

miR-494 Sensitizes Gastric Cancer Cells to TRAIL Treatment Through Downregulation of Survivin.

Cell Physiol Biochem 2018 7;51(5):2212-2223. Epub 2018 Dec 7.

Department of Internal Medicine, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou,

Background/aims: TNF-related apoptosis-inducing ligand (TRAIL) is a novel and low-toxic anti-tumor drug used for various cancers. However, cancer cells usually develop mechanisms to acquire the resistance against TRAIL. Among these changes, dysregulation of microRNAs (miRNAs) usually occurs in cancer cells and is responsible for induction of drug resistance. Read More

View Article
December 2018

RNA-Seq Analyses of the Role of miR-21 in Acute Pancreatitis.

Cell Physiol Biochem 2018 7;51(5):2198-2211. Epub 2018 Dec 7.

Institute for Brain Research and Rehabilitation, Guangdong Key Laboratory of Mental Health and Cognitive Science, Center for Studies of Psychological Application, South China Normal University, Guangzhou,

Background/aims: Our previous study demonstrated that a deficiency of microRNA 21 (miR-21) protects mice from acute pancreatitis, yet the underlying molecular networks associated with miR-21 in pancreatitis and pancreatitis-associated lung injury remain unexplored.

Methods: We used next generation sequencing to analyze gene expression profiles of pancreatic tissues from wild-type (WT) and miR-21 knockout (KO) mice treated with caerulein by using a 1-day treatment protocol. The Database for Annotation, Visualization, and Integrated Discovery gene annotation tool and Ingenuity Pathway Analysis were used to analyze the molecular pathways, while quantitative real-time PCR, western blotting, and immunohistochemistry were used to explore the molecular mechanisms. Read More

View Article
December 2018
3 Reads

Expression Levels of microRNAs miR-93 and miR-200a in Pancreatic Adenocarcinoma with Special Reference to Differentiation and Relapse-Free Survival.

Oncology 2018 Dec 11:1-7. Epub 2018 Dec 11.

Department of Pathology, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.

Objectives: Protein levels of the transcription factor nuclear factor erythroid-derived 2-like 2 (Nrf2) and its inhibitor Kelch-like ECH-associated protein 1 (Keap1) have been proposed as prognostic factors in pancreatic ductal adenocarcinomas (PDACs). These cellular redox-state-regulating enzymes are targeted by several microRNAs, including miR-93 and miR-200a.

Methods: We assessed mRNA levels of Nrf2 and Keap1 and tissue expression of miR-93 and miR-200a in 51 patients with surgically treated PDAC. Read More

View Article
December 2018

Postpartum Hemophagocytic Lymphohystiocytosis: A New Entity Is Born.

Acta Haematol 2018 Dec 7;141(1):61-62. Epub 2018 Dec 7.

Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.

View Article
December 2018

Biology of Nodal Spread in Colon Cancer: Insights from Molecular and Genetic Studies.

Eur Surg Res 2018 Dec 11;59(5-6):361-370. Epub 2018 Dec 11.

Division of Colorectal Surgery, Department of Surgery, University of Michigan, Ann Arbor, Michigan,

Colorectal cancer (CRC) lymph node metastases are common but their genetics and the mechanism whereby these metastases occur are not well understood. Here we present recent data regarding genetic heterogeneity in primary CRCs and their metastasis. In addition, we explain the different potential models describing the mechanisms of metastasis and the data supporting them. Read More

View Article
December 2018

Simultaneous optimization of isocenter locations and sector duration in radiosurgery.

Phys Med Biol 2018 Dec 11. Epub 2018 Dec 11.

Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, CANADA.

Stereotactic radiosurgery is an effective technique to treat brain tumors for which several inverse planning methods may be appropriate. We propose an integer programming model to simultaneous sector duration and isocenter optimization (SDIO) problem for Leksell Gamma Knife{\textregistered} Icon{\texttrademark} (Elekta, Stockholm, Sweden) to tractably incorporate treatment time. We devise a Benders decomposition scheme to solve the SDIO problem to optimality. Read More

View Article
December 2018

Stability and mean residence times for hybrid epithelial/mesenchymal phenotype.

Phys Biol 2018 Dec 11. Epub 2018 Dec 11.

Physics, Indian Institute of Science Education and Research (IISER) Kolkata, Kolkata, INDIA.

Cancer metastasis and drug resistance remain unsolved clinical challenges. A phenotypic transition that is often implicated in both these processes is Epithelial-Mesenchymal Transition (EMT) during which epithelial cells weaken their cell-cell adhesion and gain traits of migration and invasion, typical of mesenchymal cells. However, recent studies indicate that apart from these two states, cells can also exist in one or more hybrid E/M state(s) which plays an aggressive role in progression of the disease. Read More

View Article
December 2018

Role and mechanisms of a three-dimensional bioprinted microtissue model in promoting proliferation and invasion of growth-hormone-secreting pituitary adenoma cells.

Biofabrication 2018 Dec 11. Epub 2018 Dec 11.

Department of Mechanical Engineering, Biomanufacturing Center, Tsinghua University, Beijing, CHINA.

Growth-hormone-secreting pituitary adenoma (GHSPA) is a benign tumour with a high incidence and large economic burden, which greatly affects quality of life. The aetiological factors are yet to be clarified for GHSPA. Conventional two-dimensional (2D) monolayer culture of tumour cells cannot ideally reflect the growth status of tumours in the physiological environment, and insufficiencies of in vitro models have severely restricted the progress of cancer research. Read More

View Article
December 2018

Piezoelectric barium titanate nanostimulators for the treatment of glioblastoma multiforme.

J Colloid Interface Sci 2018 Dec 4;538:449-461. Epub 2018 Dec 4.

Istituto Italiano di Tecnologia, Smart Bio-Interfaces, Viale Rinaldo Piaggio 34, 56025 Pontedera, Italy; Politecnico di Torino, Department of Mechanical and Aerospace Engineering, Corso Duca degli Abruzzi 24, 10129 Torino, Italy. Electronic address:

Major obstacles to the successful treatment of gliolastoma multiforme are mostly related to the acquired resistance to chemotherapy drugs and, after surgery, to the cancer recurrence in correspondence of residual microscopic foci. As innovative anticancer approach, low-intensity electric stimulation represents a physical treatment able to reduce multidrug resistance of cancer and to induce remarkable anti-proliferative effects by interfering with Ca and K homeostasis and by affecting the organization of the mitotic spindles. However, to preserve healthy cells, it is utterly important to direct the electric stimuli only to malignant cells. Read More

View Article
December 2018

Differences in perceptions of e-cigarettes across daily and non-daily users.

Addict Behav 2018 Dec 5;90:415-420. Epub 2018 Dec 5.

Department of Psychology, University of Houston, Houston, TX, United States; Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, United States; Health Institute, University of Houston, Houston, TX, United States. Electronic address:

Objective: E-cigarette use has increased significantly over the past decade. Among the growing population of e-cigarette users, several pattern-based subgroups have emerged, including daily and non-daily users. Daily users are at greater risk for experiencing negative health consequences from use. Read More

View Article
December 2018
1 Read

Transition of cancer in populations in India.

Cancer Epidemiol 2018 Dec 8;58:111-120. Epub 2018 Dec 8.

Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India.

Background & Objectives: An assessment of transition of cancer in India during the past 30 years, according to changes in demographic and epidemiologic risk factors was undertaken.

Materials & Methods: Cancer registry data (http://www.ncdirindia. Read More

View Article
December 2018

A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer.

Cancer Epidemiol 2018 Dec 8;58:104-110. Epub 2018 Dec 8.

Department of Bioinformatics & Applied Sciences, Indian Institute of Information Technology, Allahabad, 211015, India. Electronic address:

Pancreatic cancer remains the fourth leading cause of cancer-related death in the world, and will continue to become the number two cause of cancer-related death unless a remarkable breakthrough is achieved. With a slim chance of early diagnosis, surgery can only provide a median survival of 17-23 months. The presence of a dense stroma makes this cancer resilient to chemotherapy, with very few potent inhibitors like nab paclitaxelin available that can work in combination with chemotherapeutic agents. Read More

View Article
December 2018
1 Read

An LC-MS/MS method for quantification of abiraterone, its active metabolites D(4)-abiraterone (D4A) and 5α-abiraterone, and their inactive glucuronide derivatives.

J Chromatogr B Analyt Technol Biomed Life Sci 2018 Dec 4;1104:249-255. Epub 2018 Dec 4.

Pharmacogenomics Laboratory, Centre Hospitalier Universitaire (CHU) de Québec, - Université Laval Research Center and Faculty of Pharmacy, Laval University, Québec city, QC, Canada; Canada Research Chair in Pharmacogenomics, Canada. Electronic address:

Abiraterone acetate (AA) is a prodrug of abiraterone, a selective and potent steroidal cytochrome P450 17alpha- hydroxylase-17,20-lyase (CYP17A1) blocking androgen synthesis in the treatment of advanced prostate cancer. Abiraterone (Abi) is metabolized to D(4)-abiraterone (D4A) directly blocking CYP17A1 and other steroidogenic enzymes and antagonizing the androgen receptor (AR). D4A is converted by 5α-reductase to 3-keto-5α-abiraterone (5α-Abi), an AR agonist. Read More

View Article
December 2018

A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo.

Colloids Surf B Biointerfaces 2018 Dec 4;175:231-238. Epub 2018 Dec 4.

Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:

Conventional chemotherapy suffers from several drawbacks, including toxic side effects together with the development of resistance to the chemical agents. Therefore, exploring alternative therapeutic approaches as well as developing targeted delivery systems are in demand. Oligonucleotide-based therapy has emerged as a promising and alternative procedure for treating malignancies involving gene-related diseases. Read More

View Article
December 2018

Impact of upstream oil extraction and environmental public health: A review of the evidence.

Sci Total Environ 2018 Dec 4;657:187-199. Epub 2018 Dec 4.

Department of Preventive Medicine, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States of America.

Upstream oil extraction, which includes exploration and operation to bring crude oil to the surface, frequently occurs near human populations. There are approximately 40,000 oil fields globally and 6 million people that live or work nearby. Oil extraction can impact local soil, water, and air, which in turn can influence community health. Read More

View Article
December 2018
1 Read

Analysis of Single Nucleotide Polymorphisms in the Gamma Block of the Major Histocompatibility Complex in Association with Clinical Outcomes of Hematopoietic Cell Transplantation: A CIBMTR Study.

Biol Blood Marrow Transplant 2018 Dec 8. Epub 2018 Dec 8.

Cleveland Clinic Foundation, Cleveland, OH.

HLA haplotype mismatches have been associated with higher risk of acute graft versus host disease (aGVHD) in patients receiving HLA matched unrelated donor (URD) hematopoietic cell transplant (HCT) unrelated donors. The Gamma block (GB) is located in the central MHC region between beta and delta blocks (encoding C & B and DR & DQ antigens, respectively). GB contains many inflammatory and immune regulatory genes such as Bf, C2 and C4 genes. Read More

View Article
December 2018

Human rhinovirus infections in hematopoietic cell transplant recipients: risk score for progression to lower respiratory tract infection.

Biol Blood Marrow Transplant 2018 Dec 8. Epub 2018 Dec 8.

Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N Seattle, WA 98109. Electronic address:

Human rhinovirus lower respiratory tract infection is associated with mortality following hematopoietic cell transplantation; however, risk factors for lower respiratory tract infection are not well characterized. We sought to develop a risk score for progression to lower respiratory tract infection from upper respiratory tract infection in hematopoietic cell transplantation recipients. Risk factors for lower respiratory tract infection within 90 days were analyzed using Cox regression among hematopoietic cell transplantation recipients with rhinovirus upper respiratory tract infection between 1/2009-3/2016. Read More

View Article
December 2018

Portal vein embolization DOES not AFFECT the long-term survival and risk of cancer recurrence among colorectal liver metastases patients: A prospective cohort study.

Int J Surg 2018 Dec 8. Epub 2018 Dec 8.

Service de chirurgie hépatobiliaire et pancréatique et de transplantation, Département de chirurgie, Centre Hospitalier de l'Université de Montréal, Site St-Luc, Montréal, QC, Canada.

Background: Previous studies comparing the survival outcomes of liver resections with and without preoperative portal vein embolization (PVE) for colorectal liver metastases (CLM) have linked PVE to higher rate of tumor progression, lower overall survival (OS) and lower disease-free survival (DFS). The lack of adjusted models to compare these outcomes is a limitation of these studies since patients requiring PVE may differ significantly from the ones receiving upfront surgery.

Materials And Methods: Prospective cohort study of 128 patients undergoing CLM resection. Read More

View Article
December 2018

Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediatric patients with acute lymphoblastic leukemia.

Eur J Pharm Sci 2018 Dec 8. Epub 2018 Dec 8.

Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, USA. Electronic address:

Background: Sirolimus is increasingly investigated as a new targeted therapy in pediatric populations. To date, population pharmacokinetic (PK) studies have identified several factors that explain in part the large between-patient variability in sirolimus PK. However, within-patient variability in sirolimus PK is not well documented. Read More

View Article
December 2018

Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.

Cancer Cell 2018 Dec;34(6):996-1011.e8

Finsen Laboratory, Rigshospitalet, DK-2200, Copenhagen, Denmark; Biotech Research & Innovation Centre (BRIC), University of Copenhagen, DK-2200, Copenhagen, Denmark; European Molecular Biology Laboratory (EMBL), Genome Biology Unit, 69120 Heidelberg, Germany; Charité Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin, Germany. Electronic address:

Identifying the earliest somatic changes in prostate cancer can give important insights into tumor evolution and aids in stratifying high- from low-risk disease. We integrated whole genome, transcriptome and methylome analysis of early-onset prostate cancers (diagnosis ≤55 years). Characterization across 292 prostate cancer genomes revealed age-related genomic alterations and a clock-like enzymatic-driven mutational process contributing to the earliest mutations in prostate cancer patients. Read More

View Article
December 2018

Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer.

Cancer Cell 2018 Dec;34(6):954-969.e4

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for Molecular Medicine and Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan; Department of Biotechnology, Asia University, Taichung 413, Taiwan. Electronic address:

Multiple mechanisms of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been identified in EGFR-mutant non-small cell lung cancer (NSCLC); however, recurrent resistance to EGFR TKIs due to the heterogeneous mechanisms underlying resistance within a single patient remains a major challenge in the clinic. Here, we report a role of nuclear protein kinase Cδ (PKCδ) as a common axis across multiple known TKI-resistance mechanisms. Specifically, we demonstrate that TKI-inactivated EGFR dimerizes with other membrane receptors implicated in TKI resistance to promote PKCδ nuclear translocation. Read More

View Article
December 2018
23.523 Impact Factor

Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling.

Cancer Cell 2018 Dec;34(6):922-938.e7

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA; The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address:

Drug resistance represents a major challenge to achieving durable responses to cancer therapeutics. Resistance mechanisms to epigenetically targeted drugs remain largely unexplored. We used bromodomain and extra-terminal domain (BET) inhibition in neuroblastoma as a prototype to model resistance to chromatin modulatory therapeutics. Read More

View Article
December 2018

Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia.

Cancer Cell 2018 Dec;34(6):906-921.e8

Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW 2052, Australia. Electronic address:

Glucocorticoids play a critical role in the treatment of lymphoid malignancies. While glucocorticoid efficacy can be largely attributed to lymphocyte-specific apoptosis, its molecular basis remains elusive. Here, we studied genome-wide lymphocyte-specific open chromatin domains (LSOs), and integrated LSOs with glucocorticoid-induced RNA transcription and chromatin modulation using an in vivo patient-derived xenograft model of acute lymphoblastic leukemia (ALL). Read More

View Article
December 2018

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.

Cancer Cell 2018 Dec;34(6):893-905.e8

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA; Breast Medicine Service, Department of Medicine, MSKCC, New York, NY 10065, USA; Weill-Cornell Medical College, New York, NY 10065, USA. Electronic address:

Cyclin dependent kinase 4/6 (CDK4/6) inhibitors (CDK4/6i) are effective in breast cancer; however, drug resistance is frequently encountered and poorly understood. We conducted a genomic analysis of 348 estrogen receptor-positive (ER) breast cancers treated with CDK4/6i and identified loss-of-function mutations affecting FAT1 and RB1 linked to drug resistance. FAT1 loss led to marked elevations in CDK6, the suppression of which restored sensitivity to CDK4/6i. Read More

View Article
December 2018
1 Read

BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.

Cancer Cell 2018 Dec;34(6):879-891

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Parkville, VIC 3010, Australia. Electronic address:

Defects in apoptotic cell death can promote cancer and impair responses of malignant cells to anti-cancer therapy. Pro-survival BCL-2 proteins prevent apoptosis by keeping the cell death effectors, BAX and BAK, in check. The BH3-only proteins initiate apoptosis by neutralizing the pro-survival BCL-2 proteins. Read More

View Article
December 2018

Immunodivergence in Metastatic Colorectal Cancer.

Cancer Cell 2018 Dec;34(6):876-878

Clinica Universidad de Navarra, Pamplona, Spain; CIBERONC, Madrid, Spain; Center for applied Medical Research (CIMA), Pamplona, Spain; IDISNA, Pamplona, Spain. Electronic address:

Van den Eynde et al. publish in this issue of Cancer Cell that metastatic colorectal cancer shows marked heterogeneity in T cell infiltration among different lesions and patients. Measurements of T cell infiltration in metastases by immunoscore offer some prognostic information and support immune editing by coevolving adaptive immune responses. Read More

View Article
December 2018

Initiation and Evolution of Early Onset Prostate Cancer.

Cancer Cell 2018 Dec;34(6):874-876

Hematology-Oncology Division, Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Electronic address:

In this issue of Cancer Cell, Gerhauser et al. analyze early-onset prostate cancers, showing roles for androgen receptor-driven rearrangements, an early APOBEC-driven mutational mechanism, and ESRP1 gene duplication. Through integration of whole-genome, transcriptome, and methylome data, they identify high-risk subgroups and develop an algorithm that may predict molecular evolution. Read More

View Article
December 2018

From Basic Knowledge to Effective Therapies.

Cancer Cell 2018 Dec;34(6):871-873

Division of Cancer Epigenomics, German Cancer Research Center, Heidelberg, Germany; The German Cancer Research Consortium. Electronic address:

In this issue of Cancer Cell, Ott et al. use integrative analysis of histone ChIP-seq and ATAC-seq to describe enhancer-based regulatory circuits in chronic lymphocytic leukemia. This work identified and validated transcription factor PAX5 as main driver of an oncogenic circuitry, which can be disrupted by BET bromodomain inhibition. Read More

View Article
December 2018

Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: BIM Finally.

Cancer Cell 2018 Dec;34(6):869-871

Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA; Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA; Department of Systems Biology, Columbia University, New York, NY 10032, USA. Electronic address:

Glucocorticoid resistance represents a major challenge in treating acute lymphoblastic leukemia. In this issue of Cancer Cell, Jing and colleagues show epigenetic deregulation of glucocorticoid-induced BIM activation in glucocorticoid-resistant leukemia cells, and restore glucocorticoid-receptor-induced BIM upregulation with DNA demethylating agents to effectively enhance glucocorticoid response. Read More

View Article
December 2018

The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients.

Cancer Cell 2018 Dec;34(6):1012-1026.e3

INSERM, Laboratory of Integrative Cancer Immunology, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot; Centre de Recherche des Cordeliers, 75006 Paris, France. Electronic address:

Treatment of metastatic colorectal cancer is based upon the assumption that metastases are homogeneous within a patient. We quantified immune cell types of 603 whole-slide metastases and primary colorectal tumors from 222 patients. Primary lesions, and synchronous and metachronous metastases, had a heterogeneous immune infiltrate and mutational diversity. Read More

View Article
December 2018
2 Reads

The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via down-regulating osteopontin.

Int J Biol Macromol 2018 Dec 8. Epub 2018 Dec 8.

Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China.

Acquired resistance to chemotherapy is a frequent challenge in cancer care and one of the leading causes for failing breast cancer therapies. There is accumulative clinical and experimental evidence indicating that microRNAs (miRNAs) play a crucial role in developing therapeutic resistance in cancer cells. We aimed to explore key miRNAs and associated mechanisms by which breast cancer develops chemoresistance. Read More

View Article
December 2018
1 Read

Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting Clinicopathologic features of upper urinary tract urothelial carcinoma.

Hum Pathol 2018 Dec 8. Epub 2018 Dec 8.

Department of Pathology, University of Michigan, 2800 Plymouth Road, Building 35, Ann Arbor, MI 48109, USA; Michigan Center for Translational Pathology, 5309 CCC 5940, 1500 E. Medical Center Drive, Ann Arbor, MI, 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, 1500 E Medical Center Drive, Ann Arbor, MI, 48109, USA. Electronic address:

5% of urothelial carcinoma occurs in the upper urinary tract (UUT), a challenging location to biopsy. We aim to evaluate concordance between biopsy, cytology, and resection specimens in a large upper tract urothelial carcinoma (UTUC) cohort.117 UTUC resections with UUT biopsy and/or cytology specimens from 2000-2016 were retrieved; pathologic material was re-reviewed, evaluated for concordance, and correlated with clinical information. Read More

View Article
December 2018

Molecular characterization of metaplastic breast carcinoma via next generation sequencing.

Hum Pathol 2018 Dec 8. Epub 2018 Dec 8.

Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte 91010, USA.

Metaplastic breast carcinoma (MBC) is a rare subtype of breast cancer with variable morphology. MBC is more often triple negative (ER-, PR-, HER2-) and is associated with poorer clinical outcome when compared to infiltrating ductal carcinoma. The purpose of our study is to identify molecular alterations in MBC using next generation sequencing (NGS) which may aid chemotherapy selection and use of targeted therapy. Read More

View Article
December 2018

Clinicopathologic and prognostic significance of MKK4 and MKK7 in resectable pancreatic ductal adenocarcinoma.

Hum Pathol 2018 Dec 8. Epub 2018 Dec 8.

Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100730, China. Electronic address:

Mitogen-activated protein kinase kinase 4 (MKK4) and mitogen-activated protein kinase kinase 7 (MKK7) were shown to regulate biological behavior in many malignancies. In pancreatic ductal adenocarcinoma (PDAC), it remains controversial whether MKK4 and MKK7 have pro-oncogenic or tumor-suppressive activities. Furthermore, their clinicopathologic and prognostic implications are unknown. Read More

View Article
December 2018

Thymic epithelial neoplasms with sebaceous differentiation: a clinicopathological and Immunohistochemical study of 8 cases.

Hum Pathol 2018 Dec 8. Epub 2018 Dec 8.

Department of Pathology, The university of Texas, M D Anderson Cancer Center, Houston, TX. Electronic address:

Eight cases of primary thymic epithelial neoplasms corresponding to seven thymomas and one thymic carcinoma with sebaceous differentiation are presented. The patients are five men and three women between the ages of 45 and 63years (average: 54years) who presented with non-specific symptomatology related to their mediastinal mass. All patients underwent complete surgical resection of the mediastinal mass. Read More

View Article
December 2018

GNAQ Mutations in Diffuse and Solitary Choroidal Hemangiomas.

Ophthalmology 2018 Dec 8. Epub 2018 Dec 8.

Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical Center, New York, NY.

Purpose: GNAQ mutations have been identified in port wine stains (both syndromic and non-syndromic) and melanocytic ocular neoplasms. This study investigates the presence of GNAQ mutations in diffuse- (those associated with Sturge-Weber syndrome (SWS)) and solitary choroidal hemangiomas.

Participants: Tissue from 11 patients with the following diagnoses: port wine stain (n = 3), diffuse choroidal hemangioma (n = 1), solitary choroidal hemangioma (n = 6), choroidal nevus (n =1) METHODS: Ten specimens were interrogated with Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT), a hybridization capture-based next-generation sequencing assay for targeted deep sequencing of all exons and selected introns of 468 key cancer genes in formalin-fixed, paraffin-embedded tumors. Read More

View Article
December 2018
1 Read

Mathematical analysis of a tumour-immune interaction model: A moving boundary problem.

Math Biosci 2018 Dec 8. Epub 2018 Dec 8.

Department of Mathematical Sciences, Stellenbosch University, Private Bag X1 Matieland, 7602, South Africa. Electronic address:

A spatio-temporal mathematical model, in the form of a moving boundary problem, to explain cancer dormancy is developed. Analysis of the model is carried out for both temporal and spatio-temporal cases. Stability analysis and numerical simulations of the temporal model replicate experimental observations of immune-induced tumour dormancy. Read More

View Article
December 2018

Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction.

J Oncol Pract 2018 Dec;14(12):e823-e833

Yale New Haven Hospital; Yale School of Medicine; Yale Cancer Center; Smilow Cancer Hospital; and Community Health Educators Group, New Haven, CT.

Purpose:: Many US academic centers have acquired community practices to expand their clinical care and research footprint. The objective of this assessment was to determine whether the acquisition and integration of community oncology practices by Yale/Smilow Cancer Hospital improved outcomes in quality of care, disease team integration, clinical trial accrual, and patient satisfaction at network practice sites.

Methods:: We evaluated quality of care by testing the hypothesis that core Quality Oncology Practice Initiative measures at network sites that were acquired in 2012 were significantly different after their 2016 integration into the network. Read More

View Article
December 2018
  • Page 1 of 75505